Literature DB >> 9634638

Mechanisms regulating the binding activity of CD44 to hyaluronic acid.

D Liu1, T Liu, R Li, M S Sy.   

Abstract

CD44 is a cell surface glycoprotein present on many cell types. Many CD44 isoforms have been identified. All CD44 isoforms utilize identical transmembrane and cytoplasmic domains. The hematopoietic form of CD44 (CD44H) is the major CD44 protein present on normal human lymphocytes and monocytes. One of the ligands for CD44 is hyaluronic acid (HA), a polymer consisting of repeat units of disaccharide; N-acetyl-D-glucosamine and N-acetyl-D-glucuronic acid. Since HA is present ubiquitously in extracellular matrix and in circulation, promiscuous binding of HA to CD44 may have undesirable affect. Similar to other adhesion molecules, binding of HA to cell surface CD44 requires regulation. In this review, we summarized our studies using a human lymphoma cell line, Jurkat. We found that binding of CD44+ Jurkat transfectants to HA requires cellular activation. Cellular activation induces the reorganization of the cytoskeleton proteins. Reorganization of cytoskeletal proteins results in clustering of CD44 on the cell surface. Clustering of CD44 on the cell surface is a prerequisite for the homodimerization of CD44. Our studies on Jurkat transfectants and results from other investigators suggest that interactions between CD44 and HA is a dynamic process and requires the participation of different cellular components; depending of the nature of the cell type and/or the nature of the activation signals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634638     DOI: 10.2741/a307

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

1.  Hyaluronic acid based materials for intestine tissue engineering: a morphological and biochemical study of cell-material interaction.

Authors:  A Esposito; A Mezzogiorno; A Sannino; A De Rosa; D Menditti; V Esposito; L Ambrosio
Journal:  J Mater Sci Mater Med       Date:  2006-12       Impact factor: 3.896

2.  Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators.

Authors:  A Ariel; O Lider; A Brill; L Cahalon; N Savion; D Varon; R Hershkoviz
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

3.  Two novel functions of hyaluronidase-2 (Hyal2) are formation of the glycocalyx and control of CD44-ERM interactions.

Authors:  Cecile Duterme; Jeannine Mertens-Strijthagen; Markku Tammi; Bruno Flamion
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

4.  Targeted drug delivery utilizing protein-like molecular architecture.

Authors:  Evonne M Rezler; David R Khan; Janelle Lauer-Fields; Mare Cudic; Diane Baronas-Lowell; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-03-31       Impact factor: 15.419

5.  Hyaluronan-Conjugated Carbon Quantum Dots for Bioimaging Use.

Authors:  Bedia Begüm Karakoçak; Amine Laradji; Tina Primeau; Mikhail Y Berezin; Shunqiang Li; Nathan Ravi
Journal:  ACS Appl Mater Interfaces       Date:  2020-12-23       Impact factor: 9.229

6.  CD44 activation state regulated by the CD44v10 isoform determines breast cancer proliferation.

Authors:  Qian Guo; Yiwen Liu; Yiqing He; Yan Du; Guoliang Zhang; Cuixia Yang; Feng Gao
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

7.  The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering.

Authors:  Cuixia Yang; Manlin Cao; Hua Liu; Yiqing He; Jing Xu; Yan Du; Yiwen Liu; Wenjuan Wang; Lian Cui; Jiajie Hu; Feng Gao
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

8.  Incorporation of Collagen and Hyaluronic Acid to Enhance the Bioactivity of Fibrin-Based Hydrogels for Nucleus Pulposus Regeneration.

Authors:  Jennifer Gansau; Conor Timothy Buckley
Journal:  J Funct Biomater       Date:  2018-07-10

Review 9.  Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.

Authors:  Anna Aureli; Beatrice Marziani; Tommaso Sconocchia; Maria Ilaria Del Principe; Elisa Buzzatti; Gianmario Pasqualone; Adriano Venditti; Giuseppe Sconocchia
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.